ライフサイエンスコーパス: phase II clinical trial

1 (131)I-MIBG) and tested the combination in a phase II clinical trial.

2 2) for 5 consecutive days every 3 weeks in a phase II clinical trial.

3 V) previously shown to improve survival in a phase II clinical trial.

4 chemotherapy was evaluated in a prospective phase II clinical trial.

5 with inflammatory breast cancer treated in a Phase II clinical trial.

6 ne evaluations before beginning a phase I or phase II clinical trial.

7 alpha, 444 septic patients were studied in a phase II clinical trial.

8 nsecutive assessable patients entered onto a phase II clinical trial.

9 ive metastatic breast cancer in a randomized phase II clinical trial.

10 tered to 38 patients with 45 infections in a phase II clinical trial.

11 tibody yielded little efficacy in a previous phase II clinical trial.

12 as applied to tumor biopsies obtained from a Phase II clinical trial.

13 th resin (90)Y-microspheres in a prospective phase II clinical trial.

14 or influenza treatment, was assessed in this phase II clinical trial.

15 models reduces H2AFY levels in a randomized phase II clinical trial.

16 y difficult to gather enough children into a phase II clinical trial.

17 against carcinoid/neuroendocrine tumors in a phase II clinical trial.

18 der tissue substitutes has led to an ongoing phase II clinical trial.

19 e/Abl dual-kinase inhibitor that is entering phase II clinical trials.

20 rug development candidate OZ277, which is in phase II clinical trials.

21 in multiple animal models of diabetes and in phase II clinical trials.

22 nimals to humans, especially for phase I and phase II clinical trials.

23 We recommend this dose for phase II clinical trials.

24 tumor models and is currently in Phase I and Phase II clinical trials.

25 rs without associated toxicity and is now in phase II clinical trials.

26 These drugs are currently being evaluated in phase II clinical trials.

27 ated from a marine tunicate, is currently in phase II clinical trials.

28 is a highly cytotoxic antimitotic peptide in phase II clinical trials.

29 chemotherapeutic drug candidate currently in Phase II clinical trials.

30 t Bcr-Abl-positive cells and is currently in Phase II clinical trials.

31 120 mg/m2 infused over 1 h should be used in Phase II clinical trials.

32 ated, Et 743 is presently being evaluated in phase II clinical trials.

33 se apoenzyme is being tested as a vaccine in phase II clinical trials.

34 ed antifolate currently undergoing extensive Phase II clinical trials.

35 atients were enrolled in two Phase I and one Phase II clinical trials.

36 FLA is currently being evaluated in ongoing phase II clinical trials.

37 ks significant mTOR activity and is entering Phase II clinical trials.

38 ent in cancer chemotherapy with compounds in phase II clinical trials.

39 he anti-EGFL7 dose currently being tested in phase II clinical trials.

40 rich tumor type, were treated with JX-594 on phase II clinical trials.

41 IFN-I blocking studies have reached phase II clinical trials.

42 rrant further exploration of R-RIT in larger phase II clinical trials.

43 Compound 8 is presently in phase II clinical trials.

44 ration inhibitor 14 (BIIB021) that completed phase II clinical trials.

45 not achieve SVR in the control arms of three Phase II clinical trials.

46 hown neurofibroma arrest in vitro and are in phase II clinical trials.

47 IRB-796 is a p38alpha inhibitor that reached Phase II clinical trials.

48 irst-in-class anticancer agent, currently in phase II clinical trials.

49 h in nonclinical studies and is currently in phase II clinical trials.

50 and PK profile in humans and is currently in phase II clinical trials.

51 DNA-interactive agent that is about to enter phase II clinical trials.

52 on of tumor growth is not easily assessed in phase II clinical trials.

53 phosphate and serine pro-drug forms is under phase II clinical trials.

54 as well as drug candidates that have entered phase II clinical trials.

55 a development candidate and is presently in phase II clinical trials.

56 es and is currently being tested in multiple phase II clinical trials.

57 Forty-four patients were enrolled in this Phase II clinical trial, 18 metformin and 26 insulin pat

58 In a multicenter phase II clinical trial, 37 patients with these poor ris

59 CR1 antagonist BX 471, which is currently in Phase II clinical trials (4).

60 lthough flavopiridol is currently undergoing phase II clinical trials, acquired cellular resistance t

61 Standardization of phase II clinical trials across individual institutions

62 ts have encouraged development of an ongoing phase II clinical trial aimed to evaluate the efficacy o

63 combination with a PKC-vartheta inhibitor in phase II clinical trial, almost completely suppressed HI

64 a Syk inhibitor that successfully completed phase II clinical trials, also exhibits some undesirable

65 In 2002, a Phase II clinical trial (AN1792) was halted due to menin

66 AUY922 is in phase II clinical trial and, in combination with a PKC-v

67 In MS, imaging has allowed smaller Phase II clinical trials and contributed to medicine dif

68 he two PBD moieties, is currently undergoing phase II clinical trials and current research is focused

69 re for 35 case patients who received care on phase II clinical trials and for 35 matched controls (ba

70 has been evaluated as a single agent in two phase II clinical trials and in combination with chemoth

71 ferred partial protection against malaria in phase II clinical trials and is currently being evaluate

72 specific and potent lowering of Lp(a) are in phase II clinical trials and provide a tool to test the

73 igational center involving two Phase I and a Phase II clinical trials approved by the Food and Drug A

74 Cemadotin is in phase II clinical trials as a promising cancer chemother

75 tanocene dichloride, Cp(2)TiCl(2), is now in phase II clinical trials as an anticancer drug, but its

76 study was a double-blind, placebo-controlled phase II clinical trial assessing influenza viral load a

77 modality is currently under investigation in phase II clinical trials at several institutions.

78 In this phase II clinical trial, based upon the results of our p

79 hesis, two hydrophobic drugs that had failed phase II clinical trials because of excess toxicity at d

80 Flavopiridol, an anticancer drug in phase II clinical trials, binds to the ATP site of CDK9

81 These data indicate that Phase II clinical trials combining radiolabeled antibody

82 Finally, phase I and phase II clinical trials conducted by us and others show

83 Moreover, a recent phase II clinical trial demonstrated the antipsychotic e

84 Our studies of melanoma patients in phase II clinical trials demonstrated prognostic signifi

85 We describe an innovative phase II clinical trial design for evaluating the additi

86 We review two Bayesian phase II clinical trial designs that account explicitly

87 We now report results from the first phase II clinical trial developed exclusively for SCUC,

88 This phase II clinical trial evaluated the combination of CIS

89 A phase II clinical trial evaluating the effects of good m

90 A phase II clinical trial evaluating the effects of good m

91 caspase inhibitor is now the subject of two Phase II clinical trials, evaluating its safety and effi

92 radiotracer, Flurpiridaz F 18, has undergone phase II clinical trial evaluation as a high-resolution

93 Chinese herb gamboges, has been approved for Phase II clinical trial for cancer therapy by Chinese FD

94 It has demonstrated efficacy in a phase II clinical trial for congestive heart failure.

95 In a recent phase II clinical trial for HNSCC patients, IRX-2, a cel

96 e was evaluated for efficacy and safety in a phase II clinical trial for women with metastatic breast

97 Compound 1 is currently in phase II clinical trials for advanced solid tumors and r

98 nesis in laboratory animals, and has entered phase II clinical trials for both Alzheimer's disease an

99 680, an Aurora kinase inhibitor currently in phase II clinical trials for cancer treatment, could ind

100 tor of histone deacetylases, is currently in phase II clinical trials for cutaneous T cell lymphomas

101 Since the majority of phase II clinical trials for patients with androgen-inde

102 AS1411 is a DNA aptamer that is in phase II clinical trials for relapsed or refractory acut

103 2C4 is currently in phase II clinical trials for several types of cancers.

104 Tideglusib is a GSK-3 inhibitor currently in phase II clinical trials for the treatment of Alzheimer

105 selective inhibitor of KSP, is currently in phase II clinical trials for the treatment of multiple t

106 is currently being evaluated in Phase I and Phase II clinical trials for the treatment of multiple t

107 ta-lap; also known as ARQ 501), currently in phase II clinical trials for the treatment of pancreatic

108 ha MAP kinase inhibitor that is currently in phase II clinical trials for the treatment of rheumatoid

109 Radiofrequency ablation has recently entered phase II clinical trials for the treatment of small rena

110 17E6 is currently in phase II clinical trials for treating cancer.

111 ng marine-based antitumor agent presently in phase II clinical trials, has been shown to interfere wi

112 Preliminary results from a phase II clinical trial have shown improved clinical out

113 human annexin V, diannexin, has completed a Phase II Clinical Trial in Kidney Transplantation (NCT00

114 cy of this schedule is being determined in a phase II clinical trial in patients with advanced breast

115 We conducted a prospective phase II clinical trial in patients with advanced NSCLC.

116 A prospective phase II clinical trial in patients with locally advance

117 In a Phase II clinical trial in poor prognosis AML, ribavirin

118 t of JNJ 39758979, which has been studied in phase II clinical trials in asthma and atopic dermatitis

119 appaB and activates p53, has progressed into phase II clinical trials in cancer.

120 from phase III clinical trials in adults and phase II clinical trials in children and adolescents dem

121 In phase II clinical trials in HIV patients, data revealed

122 ombination of melatonin with cooling support phase II clinical trials in infants with moderate and se

123 ditional kinases, are now being evaluated in Phase II clinical trials in MTC.

124 We also describe preliminary findings from phase II clinical trials in patients treated with miR-12

125 ized in the 1990s and has recently completed Phase II clinical trials in patients with leukaemia and

126 NTS AND METHODS We conducted two independent phase II clinical trials in small-cell lung cancer and n

127 -5,8-dione antitumor antibiotic that reached phase II clinical trials in the 1970s, is described.

128 trinuclear platinum drug that has undergone phase II clinical trials in the treatment of ovarian and

129 a from drug-interaction studies and 2 small, phase II clinical trials indicate that these HCV treatme

130 Phase II clinical trials inform go/no-go decisions for p

131 This is a phase II clinical trial investigating the safety and eff

132 le sclerosis patients is in progress, as are phase II clinical trials investigating the oral administ

133 ived from dendritic cells (dexosomes), and a phase II clinical trial is ongoing.

134 report that RVX-208, a compound currently in phase II clinical trials, is a BET bromodomain inhibitor

135 Tasidotin, an oncolytic drug in phase II clinical trials, is a peptide analog of the ant

136 xists, although several options supported by phase II clinical trials (methylprednisolone plus alemtu

137 ally active 1 has demonstrated efficacy in a phase II clinical trial of congestive heart failure and

138 a from an Eastern Cooperative Oncology Group phase II clinical trial of liver cancer and a phase III

139 We conducted a single-arm phase II clinical trial of single-agent platinum for mTN

140 pillary thyroid cancer (PTC), we conducted a phase II clinical trial of sorafenib targeting RAF and V

141 Indeed, phase II clinical trials of an 8-OHQ has produced encour

142 Larger and longer phase II clinical trials of anastrozole may be warranted

143 chniques and blood biomarkers in prospective phase II clinical trials of cediranib with chemoradiatio

144 clinical benefit, we conducted two parallel phase II clinical trials of recombinant vaccinia-NY-ESO-

145 The recent discovery and progression to phase II clinical trials of trihalobenzocycloheptapyridi

146 The mean age of the phase II clinical trial patients was 58.3 years versus 5

147 001 and CCI-779 are currently in phase I and phase II clinical trials, respectively, as anticancer ag

148 othelial growth factor receptor currently in phase II clinical trials, restores lapatinib and trastuz

149 Phase II clinical trials revealed that the lymphocyte-de

150 nized monoclonal antibody -- soon to undergo phase-II clinical trials -- significantly impairs the es

151 In a phase II clinical trial that treated 27 patients with me

152 erfusion regimens, an integrated approach to phase II clinical trials that incorporates multiple effi

153 In this open-label phase II clinical trial, the primary end point was tumor

154 We conducted a phase II clinical trial to determine the clinical effica

155 ) burn were prospectively randomized in this Phase II clinical trial to either metformin or insulin (

156 sortium designed a prospective, multicenter, Phase II clinical trial to investigate extending the int

157 We performed an open-label, single-arm phase II clinical trial to investigate the efficacy and

158 ]boronophenylalanine-fructose (BPA-Fr) is in Phase II clinical trials to validate BNCT as a treatment

159 2ME2 is currently in several Phase I and Phase II clinical trials under the name Panzem.

160 In a recent phase II clinical trial using banked allogeneic CTL line

161 A phase II clinical trial using low-intensity allogeneic h

162 PATIENTS AND METHODS An open-label, phase II clinical trial was conducted in newly diagnosed

163 A multiinstitutional phase II clinical trial was conducted to evaluate the ac

164 A phase II clinical trial was conducted to evaluate the fe

165 A prospective, phase II clinical trial was initiated by the Eastern Coo

166 lpha-(18)F-fluoroestradiol ((18)F-4FMFES), a phase II clinical trial was initiated to compare the PET

167 A phase II clinical trial was performed to evaluate the ef

168 uble-blind, placebo-controlled, multicenter, phase II clinical trial was undertaken using IR501 thera

169 a bacterial arginine deiminase evaluated in phase II clinical trials was reported to be immunogenic,

170 As part of a larger, phase II clinical trial, we evaluated the ability of a r

171 Two consecutive phase II clinical trials were jointly analyzed.

172 r agent perillyl alcohol (POH), presently in Phase II clinical trials, were investigated in advanced

173 Ed4T seems very promising in phase II clinical trials, whereas toxicity halted FLT de

174 A phase II clinical trial with single-agent decitabine was

175 A magnetic resonance imaging-controlled phase II clinical trial with this altered peptide ligand

176 a potential cancer chemotherapeutic agent in Phase II clinical trials, with positive responses observ

177 acid (DMXAA) is a VDA currently in advanced phase II clinical trials, yet its precise mechanism of a